Takashi Ishikawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Takashi Ishikawa has a total of 213 co-authors. Here are the top co-authors by number of shared publications:
- Akimitsu Yamada
Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Kanagawa, Japan
14 shared publications - Aparna Maiti
Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Elm & Carlton Streets, Buffalo, NY 14263, USA
14 shared publications Hiroshi Miyazaki
14 shared publications- Itaru Endo
Department of Gastroenterological Surgery Yokohama City University Graduate School of Medicine Kanagawa Japan
14 shared publications - Kazuaki Takabe
Roswell Park Comprehensive Cancer Center
14 shared publications - Krista P. Terracina
College of Medicine, Department of Surgery, University of Florida, Gainesville, Florida, USA
14 shared publications
Latest Publications
- 13 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (7) , e218523
Teaching NeuroImage: Progressive Intracranial Calcifications and Pulmonary Disease in an Infant, Consistent With Type I Interferonopathy
- 13 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (7) , e218523
Teaching NeuroImage: Progressive Intracranial Calcifications and Pulmonary Disease in an Infant, Consistent With Type I Interferonopathy
- 27 July 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (10)
Targeted Busulfan Conditioning for Cord Blood Transplantation in Newborn‐Screened Severe Combined Immunodeficiency
- 27 July 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (10)
Targeted Busulfan Conditioning for Cord Blood Transplantation in Newborn‐Screened Severe Combined Immunodeficiency
- Open Access
- 23 June 2026
- Vol. 2 (5)
Thalidomide for CGD-related inflammatory bowel disease: A randomized, double-blind trial
In this first randomized, placebo-controlled trial, thalidomide demonstrated potential efficacy and acceptable safety in patients aged 1 year or older with chronic granulomatous disease–related inflammatory bowel disease, suggesting potential as a therapeutic option without increasing the risk of infection.
- 23 June 2026
- Vol. 2 (5)
Open AccessThalidomide for CGD-related inflammatory bowel disease: A randomized, double-blind trial
In this first randomized, placebo-controlled trial, thalidomide demonstrated potential efficacy and acceptable safety in patients aged 1 year or older with chronic granulomatous disease–related inflammatory bowel disease, suggesting potential as a therapeutic option without increasing the risk of infection.
- Open Access
- 31 January 2026
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 24 (1) , 182-188
Inflammatory bowel disease in a young female patient with a novel de novo TRAF3 frameshift variant responsive to ustekinumab: a case report
Inflammatory bowel disease in a young female patient with a novel de novo TRAF3 frameshift variant responsive to ustekinumab: a case report
- 31 January 2026
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 24 (1) , 182-188
Open AccessInflammatory bowel disease in a young female patient with a novel de novo TRAF3 frameshift variant responsive to ustekinumab: a case report
Inflammatory bowel disease in a young female patient with a novel de novo TRAF3 frameshift variant responsive to ustekinumab: a case report
- 7 July 2025
- Published by Oxford University Press (OUP) in Modern Rheumatology Case Reports
- Vol. 9 (2)
Placental and breast milk transfer of belimumab in three patients with systemic lupus erythematosus treated throughout pregnancy
The safety of belimumab during pregnancy, particularly in the third trimester, remains unclear. This study aimed to assess the placental and breast milk transfer of belimumab in pregnancies complicated by systemic lupus erythematosus and to evaluate immunological effects and vaccination responses in offspring. We prospectively followed three patients with systemic lupus erythematosus who received belimumab throughout pregnancy. Belimumab concentrations were measured in maternal serum, cord blood, breast milk, and neonatal serum, along with infant development and vaccination histories. Belimumab was continued throughout pregnancy to control refractory thrombocytopenia in two cases and haemolytic anaemia in one case. All patients delivered full-term infants without obstetric complications. Overall, belimumab concentrations in cord blood and neonatal serum were comparable to those in the maternal serum, suggesting transplacental transfer. A decrease in peripheral B and transitional B cells was observed in all neonates at birth, while serum IgG levels and peripheral T cell counts were within normal ranges. Only one infant was diagnosed with a complication (left vesicoureteral reflux). Belimumab concentrations in breast milk were low, and no adverse events occurred in the vaccinated infants. Continuation of belimumab throughout pregnancy may be an option to control refractory disease activity and achieve successful outcomes in pregnancies complicated by systemic lupus erythematosus. However, careful monitoring during pregnancy and postnatal follow-up is essential to ensure safety, given that belimumab can be transferred to the placenta, detected in the neonatal peripheral blood, and affect the neonatal lymphocyte subset counts at birth.
- 7 July 2025
- Published by Oxford University Press (OUP) in Modern Rheumatology Case Reports
- Vol. 9 (2)
Placental and breast milk transfer of belimumab in three patients with systemic lupus erythematosus treated throughout pregnancy
The safety of belimumab during pregnancy, particularly in the third trimester, remains unclear. This study aimed to assess the placental and breast milk transfer of belimumab in pregnancies complicated by systemic lupus erythematosus and to evaluate immunological effects and vaccination responses in offspring. We prospectively followed three patients with systemic lupus erythematosus who received belimumab throughout pregnancy. Belimumab concentrations were measured in maternal serum, cord blood, breast milk, and neonatal serum, along with infant development and vaccination histories. Belimumab was continued throughout pregnancy to control refractory thrombocytopenia in two cases and haemolytic anaemia in one case. All patients delivered full-term infants without obstetric complications. Overall, belimumab concentrations in cord blood and neonatal serum were comparable to those in the maternal serum, suggesting transplacental transfer. A decrease in peripheral B and transitional B cells was observed in all neonates at birth, while serum IgG levels and peripheral T cell counts were within normal ranges. Only one infant was diagnosed with a complication (left vesicoureteral reflux). Belimumab concentrations in breast milk were low, and no adverse events occurred in the vaccinated infants. Continuation of belimumab throughout pregnancy may be an option to control refractory disease activity and achieve successful outcomes in pregnancies complicated by systemic lupus erythematosus. However, careful monitoring during pregnancy and postnatal follow-up is essential to ensure safety, given that belimumab can be transferred to the placenta, detected in the neonatal peripheral blood, and affect the neonatal lymphocyte subset counts at birth.
- 21 April 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (3) , e70086
Hematopoietic Cell Transplantation in a Patient With X‐Linked Chronic Granulomatous Disease With McLeod Phenotype
Background: X‐linked chronic granulomatous disease (X‐CGD) may be associated with McLeod syndrome (MLS) as a contiguous gene deletion syndrome. MLS is characterized by the loss of XK protein along with Kx antigen on red blood cell (RBC) surfaces and late‐onset neurocognitive symptoms. RBCs in healthy donors express XK protein and related Kx antigen on the surface; therefore, transfusion from random donors to patients with MLS poses a risk of Kx sensitization, leading to severe hemolysis. As the radical treatment of X‐CGD is hematopoietic cell transplantation (HCT), treating patients with coexisting X‐CGD and MLS is extremely challenging.Method: A retrospective chart review was completed for a case of X‐CGD associated with MLS who underwent HCT.Result: A 7‐year‐old boy with X‐CGD and MLS underwent HCT from a matched unrelated donor (human leukocyte antigen, 7/8 matched). Rituximab was added to busulfan‐based reduced intensity conditioning to prevent Kx sensitization. Donor RBCs were depleted from the bone marrow before infusion to prevent Kx sensitization. Neutrophil engraftment was achieved on day +19 with full donor chimerism. No hemolytic events occurred, and he is living well 2 years after HCT.Conclusion: We were able to safely perform transplantation in a patient with X‐CGD and MLS by adding rituximab and depleting RBCs from the donor bone marrow. The long‐term impact of HCT on MLS is unclear. However, HCT may improve prognosis and quality of life by reducing recurrent infections caused by X‐CGD. Moreover, this HCT method is non‐invasive, relatively simple, and easily implementable.
- 21 April 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (3) , e70086
Hematopoietic Cell Transplantation in a Patient With X‐Linked Chronic Granulomatous Disease With McLeod Phenotype
Background: X‐linked chronic granulomatous disease (X‐CGD) may be associated with McLeod syndrome (MLS) as a contiguous gene deletion syndrome. MLS is characterized by the loss of XK protein along with Kx antigen on red blood cell (RBC) surfaces and late‐onset neurocognitive symptoms. RBCs in healthy donors express XK protein and related Kx antigen on the surface; therefore, transfusion from random donors to patients with MLS poses a risk of Kx sensitization, leading to severe hemolysis. As the radical treatment of X‐CGD is hematopoietic cell transplantation (HCT), treating patients with coexisting X‐CGD and MLS is extremely challenging.Method: A retrospective chart review was completed for a case of X‐CGD associated with MLS who underwent HCT.Result: A 7‐year‐old boy with X‐CGD and MLS underwent HCT from a matched unrelated donor (human leukocyte antigen, 7/8 matched). Rituximab was added to busulfan‐based reduced intensity conditioning to prevent Kx sensitization. Donor RBCs were depleted from the bone marrow before infusion to prevent Kx sensitization. Neutrophil engraftment was achieved on day +19 with full donor chimerism. No hemolytic events occurred, and he is living well 2 years after HCT.Conclusion: We were able to safely perform transplantation in a patient with X‐CGD and MLS by adding rituximab and depleting RBCs from the donor bone marrow. The long‐term impact of HCT on MLS is unclear. However, HCT may improve prognosis and quality of life by reducing recurrent infections caused by X‐CGD. Moreover, this HCT method is non‐invasive, relatively simple, and easily implementable.
- 1 January 2025
- Published by Wiley in Pediatrics International
- Vol. 67 (1) , e70065
Robust immune response to SARS ‐ CoV ‐2 mRNA vaccines may exacerbate the clinical symptoms of A20 haploinsufficiency
- 1 January 2025
- Published by Wiley in Pediatrics International
- Vol. 67 (1) , e70065
Robust immune response to SARS ‐ CoV ‐2 mRNA vaccines may exacerbate the clinical symptoms of A20 haploinsufficiency
- Open Access
- 6 September 2024
- Published by Wiley
Successful hematopoietic cell transplantation in a patient with X-linked chronic granulomatous disease concomitant with McLeod phenotype
X-linked chronic granulomatous disease (X-CGD) may be associated with McLeod syndrome (MLS) as a contiguous gene deletion syndrome. MLS is characterized by the loss of XK protein together with Kx antigen on red blood cell (RBC) surfaces and late-onset neurocognitive symptoms. X-CGD treatment involves hematopoietic cell transplantation (HCT), and severe hemolysis may occur due to Kx antigen sensitization. Here, we report successful HCT in a 7-year-old male with X-CGD and MLS achieved by depleting RBCs from the graft and adding rituximab to the conditioning regimen. No hemolytic events occurred, and he is doing well 2 years after HCT.
- 6 September 2024
- Published by Wiley
Open AccessSuccessful hematopoietic cell transplantation in a patient with X-linked chronic granulomatous disease concomitant with McLeod phenotype
X-linked chronic granulomatous disease (X-CGD) may be associated with McLeod syndrome (MLS) as a contiguous gene deletion syndrome. MLS is characterized by the loss of XK protein together with Kx antigen on red blood cell (RBC) surfaces and late-onset neurocognitive symptoms. X-CGD treatment involves hematopoietic cell transplantation (HCT), and severe hemolysis may occur due to Kx antigen sensitization. Here, we report successful HCT in a 7-year-old male with X-CGD and MLS achieved by depleting RBCs from the graft and adding rituximab to the conditioning regimen. No hemolytic events occurred, and he is doing well 2 years after HCT.
- 25 May 2024
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 35 (1) , 174-184
Efficacy and safety of tumor necrosis factor inhibitors for systemic juvenile idiopathic arthritis: A systematic review
Objectives: This systematic review assessed the efficacy and safety of tumor necrosis factor (TNF) inhibitors in patients with systemic juvenile idiopathic arthritis (JIA). Methods: Studies were searched using PubMed, Embase, Cochrane, Ichushi-Web, and clinical trial registries (from 2000 to 2021). The risk of bias was assessed using the Cochrane Risk of Bias version 2 for randomized controlled trials (RCTs) and the manual of Minds for observational studies. Results: One RCT and 22 observational studies were included. In the RCT on infliximab, the American College of Rheumatology pediatric (ACR Pedi) 30/50/70 responses at 14 weeks were 63.8%/50.0%/22.4%, with relative risks of 1.30 [95% confidence interval (CI): 0.94–1.79]/1.48 (95% CI: 0.95–2.29)/1.89 (95% CI: 0.81–4.40), respectively. In the observational studies, ACR Pedi 30/50/70 responses for etanercept at 12 months were 76.7%/64.7%/46.4%, respectively. Infliximab treatment caused anaphylaxis in 17% and an infusion reaction in 23% of patients. The incidence of macrophage activation syndrome, serious infection, and malignancy caused by TNF inhibitors was 0–4%. Conclusions: Thus, although TNF inhibitors were relatively safe, they were unlikely to be preferentially administered in patients with systemic JIA because of their inadequate efficacy. Further studies, especially well-designed RCTs, are needed to accumulate clinical data.
- 25 May 2024
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 35 (1) , 174-184
Efficacy and safety of tumor necrosis factor inhibitors for systemic juvenile idiopathic arthritis: A systematic review
Objectives: This systematic review assessed the efficacy and safety of tumor necrosis factor (TNF) inhibitors in patients with systemic juvenile idiopathic arthritis (JIA). Methods: Studies were searched using PubMed, Embase, Cochrane, Ichushi-Web, and clinical trial registries (from 2000 to 2021). The risk of bias was assessed using the Cochrane Risk of Bias version 2 for randomized controlled trials (RCTs) and the manual of Minds for observational studies. Results: One RCT and 22 observational studies were included. In the RCT on infliximab, the American College of Rheumatology pediatric (ACR Pedi) 30/50/70 responses at 14 weeks were 63.8%/50.0%/22.4%, with relative risks of 1.30 [95% confidence interval (CI): 0.94–1.79]/1.48 (95% CI: 0.95–2.29)/1.89 (95% CI: 0.81–4.40), respectively. In the observational studies, ACR Pedi 30/50/70 responses for etanercept at 12 months were 76.7%/64.7%/46.4%, respectively. Infliximab treatment caused anaphylaxis in 17% and an infusion reaction in 23% of patients. The incidence of macrophage activation syndrome, serious infection, and malignancy caused by TNF inhibitors was 0–4%. Conclusions: Thus, although TNF inhibitors were relatively safe, they were unlikely to be preferentially administered in patients with systemic JIA because of their inadequate efficacy. Further studies, especially well-designed RCTs, are needed to accumulate clinical data.